Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent C Tam

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
The Journal of General Virology|November 19, 2013
Characterization of innate responses to influenza virus infection in a novel lung type I epithelial cell modelCarrie M Rosenberger, Rebecca L Podyminogin, Peter S Askovich, et al.
Journal of Hepatology|April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCLorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
JAMA Oncology|September 6, 2019
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical TrialGhassan K Abou-Alfa, Qian Shi, Jennifer J Knox, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Hepatology (Baltimore, Md.)|May 19, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trialGeorge Lau, Bruno Sangro, Ann-Lii Cheng, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Scientific Data|May 16, 2015
A comprehensive collection of systems biology data characterizing the host response to viral infectionBrian D Aevermann, Brett E Pickett, Sanjeev Kumar, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
The Journal of General Virology|November 19, 2013
Characterization of innate responses to influenza virus infection in a novel lung type I epithelial cell modelCarrie M Rosenberger, Rebecca L Podyminogin, Peter S Askovich, et al.
Journal of Hepatology|April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCLorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
JAMA Oncology|September 6, 2019
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical TrialGhassan K Abou-Alfa, Qian Shi, Jennifer J Knox, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Hepatology (Baltimore, Md.)|May 19, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trialGeorge Lau, Bruno Sangro, Ann-Lii Cheng, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Scientific Data|May 16, 2015
A comprehensive collection of systems biology data characterizing the host response to viral infectionBrian D Aevermann, Brett E Pickett, Sanjeev Kumar, et al.
Pageof 5